Home > Healthcare > Pharmaceuticals > Finished Drug Form > Complex Regional Pain Syndrome (CRPS) Market

Complex Regional Pain Syndrome (CRPS) Market Share

Report ID: GMI12148
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Complex Regional Pain Syndrome Market Share

The complex regional pain syndrome (CRPS) market is highly competitive, driven by rising demand for specialized pain management and advancements in neurostimulation and pharmaceutical therapies. Leading medical device and pharmaceutical companies command substantial market shares by offering targeted CRPS treatments, including innovative neurostimulation devices and refined analgesics tailored for chronic pain. Strategic moves such as partnerships, acquisitions, and technological innovations enhance their positions, enabling broader outreach across pain-related therapeutic areas, including neuropathy and post-surgical pain management. Continuous R&D investment allows these companies to capture emerging CRPS treatment segments, address specific patient needs, and reinforce their influence in the expanding global market for precision pain therapies.

Complex Regional Pain Syndrome Market Companies

Major players operating in the complex regional pain syndrome industry are:

Abbott Laboratories
AbbVie
Averitas Pharma
Boston Scientific
Collegium Pharmaceutical
Eli Lilly and Company
Mallinckrodt Pharmaceuticals
Medtronic
Nevro
Pfizer
Sandoz
Teva Pharmaceutical

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for complex regional pain syndrome was valued at approximately USD 109 million in 2023 and is expected to reach around USD 134.2 million by 2032, driven by a CAGR of over 2.4% from 2024 to 2032.

The CRPS Type I segment accounted for USD 91.2 million in 2023, representing nearly 90% of all CRPS cases, driven by its prevalence following injuries or illnesses that do not directly damage the nerves.

U.S. market generated USD 49.8 million by the end of 2032, driven by a high incidence of chronic pain conditions and a strong healthcare infrastructure.

Major players in the industry include Abbott Laboratories, AbbVie, Averitas Pharma, Boston Scientific, Collegium Pharmaceutical, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, and Medtronic.